Pseudotumor Cerebri Market Size

Global Pseudotumor Cerebri Market Overview

pseudotumor cerebri market size was valued at USD 3.51 billion in 2022. The pseudotumor cerebri market industry is projected to grow from USD 3.77 billion in 2023 to USD 7.05 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.46% during the forecast period (2023 - 2032). 

The Pseudotumor Cerebri has also been termed an idiopathic intracranial hypertension syndrome with elevated intracranial pressure. This mainly occurs predominantly in obese women of childbearing age. Headaches and also vision impairment has been mostly found within the Pseudotumor Cerebri. Most of the visual symptoms arise to be due to papilledema. Further, to this context, it has been noted down that a rise in technological advancement and an increase in the prevalence of obesity has been analyzed as well.

It mainly includes the major key drivers that drive the entire Pseudotumor Cerebri market growth. Therefore, the statistical background suggested that more than 1.9 billion individuals have been overweight and out of that, 650 million children have been overweight or obese. Therefore, the various health conditions and its effect on the body include mainly sleep apnea, kidney disease, Lyme disease, and Addison’s disease as well. On the other hand, various other elements have been included and that states the growing awareness, an increase in the incidence of pseudotumor Cerebri, and the related complications within.

In July 2022, Invex Therapeutics received approvals to initiate the Phase III IIH EVOLVE clinical trial of Presendin in Australia to treat idiopathic intracranial hypertension (IIH). The approvals consist of authorization for the Clinical Trial Notification (CTN) scheme by the Australian Therapeutic Goods Administration (TGA) and those from the Human Research Ethics Committee (HREC). Presendin, a sustained release (SR) Exenatide microsphere formulation, was created by Peptron and is designed to be administered subcutaneously on a weekly basis. In September of the previous year, Invex executed an exclusive partnership, manufacturing, and supply agreement with Peptron for Presendin in IIH for critical markets, with the exception of South Korea. The current sanction from HREC encompasses a variety of private hospital sites throughout the nation that will conduct this trial. Additionally, Invex intends to submit an additional application to the committee for a single public hospital in Australia in the near future. Australian IIH EVOLVE trial sites have been initiated by the company, and subject recruitment will commence upon the acquisition of distinct institutional authorizations. The safety and efficacy of Presendin in comparison to placebo will be evaluated over a 24-week period in this placebo-controlled, randomized, double-blind trial, which will enroll 240 newly diagnosed IIH patients. The primary endpoint of the trial is the change in intracranial pressure (ICP) from baseline, as determined by lumbar puncture.

In November 17, 2022, Peptron, Inc., a pioneer in the development of peptide-based sustained-release drug products, announced that it had successfully established bioequivalence of "PT105," a once-a-month injectable Leuprolide for the treatment of prostate cancer, breast cancer, endometriosis, and precocious puberty. Leuplin, the original medication for PT105, is one of the most successful blockbusters of the past three decades, with a total of $1.34 billion in sales and the largest global market share. It is manufactured by Takeda. The Material, Composition, and Use patents have elapsed; however, Peptron has achieved full equivalence as a result of the challenge in generic drug development in replicating Takeda's manufacturing process and technology. Peptron and Invex Therapeutics were granted phase 3 IND approvals by the U.S. in August 2022. Presendin (PT320) is regulated by the FDA, MHRA, and other organizations. Presendin's primary target is idiopathic intracranial hypertension (IIH), which currently lacks a treatment. The global market for IIH is estimated to be $1.5 billion USD. Peptron anticipates a substantial increase in demand for contract development and manufacturing services, as well as a substantial revenue potential.

Covid 19 Analysis

The sudden outbreak of the pandemic situation has led to the strong implementation of stringent lockdown across the globe. This has resulted in the disruption of the export and import activities of the Pseudotumor Cerebri. The analysis of Covid 19 has affected the entire economy and it has affected in particular 2 different ways. Firstly, it directly affects the production of the market along with the demand. Secondly, supply chain management has been disrupted along with the financial impact on the firm. Therefore, according to the analysis, the overall impact of covid 19 has been monitored which states the generative prospects of remunerative production in this market.

Pseudotumor Cerebri Market Trends

• Drivers

One of the most key driving factors of this market states the growing awareness of the market production, an increase in the enhancing framework with prior regulation, and unmet regular needs. Further, an increase in government assistance, as well as the adoption rate of the new technologies, these has been addressed to be the key driving elements. This has led to the reimbursement of the continuous contribution of the pseudotumor cerebri market along with the rise in funding.

• Restraints

One of the key restraining factors states that a few setbacks have been observed that are associated with this mentioned market. Hence, the cost of treatment, side-effects are also associated with the surgical intervention as well. This has analyzed the poor system of healthcare within the middle-income status of the countries. It attempts to portray that this particular factor has hindered the actual growth of pseudotumor cerebri market to a considerable extent.

• Challenges

One of the major challenges faced in this production of market states the risk factors and it determines the identification of it. Some of the features identified in the market clearly attempt to suggest that absence of the papilledema risks vision loss. Further, the outcomes appear to be treated aggressively with a basic identification of the patients. Hence, this appears to be magnetic and it responds to the visual outcomes for mitigation of the issue. 

• Opportunities

One of the basic opportunities of the market exclaims the increase in the market products in the global market analysis. This tends to improve the basic infrastructure with a propel to the Pseudotumor Cerebri market. Henceforth, new products launched have been initialized as an opportunist factor to flourish more globally. Henceforth, the result of flourished products has intended to make the continuation of the development process manually.

Cumulative Analysis

The Compound Annual Growth Rate (CAGR) is predicted to grow at 6.1%. Accordingly, the market growth has expanded its growth within the forecast period of 2021-2027. Various drivers such as the growing awareness of the adoption of the new technology as well as the growing demand for products. 

Value Chain Analysis

An increase in the adoption of new technology has given a rise in the market. Hence, this has contributed to the entire overall impact on the market positively. Also, the growing initiatives by the government for the development and research will improve the value chain of the Pseudotumor Cerebri Market in the upcoming years.

Pseudotumor Cerebri Market Segment Insights

According to the market segmentation of Pseudotumor Cerebri, it is segmented under the diagnosis, end-user and treatment.

Pseudotumor Cerebri Treatment Insights

Based on treatment, the concise market is basically classified under the medication, surgery, and others as well. In this section, surgery has been further classified into the optic nerve sheath fenestration, spinal fluid shunt, and also bariatric surgery. Therefore, the medication is segmented into topiramate, furosemide, acetazolamide, and others.

Pseudotumor Cerebri Diagnosis Insights

Based on diagnosis, the PCM is further segmented as fundoscopy, neuroimaging, puncture, neuroimaging and others. Lastly, 

Pseudotumor Cerebri End-User Insights

Based on end-users, the market segmentation accounts into clinics, hospitals, diagnostic centers, drug stores, pharmacies, and many more.

Pseudotumor Cerebri Regional Insights

In this section, the analysis of the regional access has been evaluated and it has been classified. Here, America has been considered to dominate the pseudotumor cerebri market and that owns towards the rise in the occurrence of the market. According to the statistical study, IOC in 2014, it has been observed that the annual incidence of the idiopathic intracranial hypertension has around 0.9 out of 100000 individuals. Further, it has been reported that the annual growth of the cost has been exceeded that includes USD 444 million. Therefore, due to the frequent hospitalization, the inclination of young workers results in a significant loss. On the other hand, the European market attempts to hold a position in this market with government support towards R&D amendments and expenditure. Asia-pacific market has been considered as the fastest growing that owns a huge patient area for development within the healthcare technology. The healthcare expenditure happens to find states the importance of the amendments within the reimbursement policies within the healthcare. This is expected to make the drive within the European pseudotumor cerebri market. Further, the Middle-East and Africa attempt to hold the lowest position in the global market due to the slow development of the market, lack of technical knowledge along with the poor facilities of medicine.

Competitive Landscape

The pseudotumor cerebri market comprises moderate competition and it initiates the importance of the several major players that compete with the global market. Hence, some of the major key players are:

• Avkare


• Beckersmith Medical Inc


• Johnson & Johnson Services


• MercuryPharma


• Phoenix Biomedical Corp


• Novast Holdings Ltd


• West-ward Pharmaceutical


• Magstim


• Integra Lifesciences


• Braun Melsungen


• Teva Pharmaceutical industries Ltd


• Lannett Company


• Elekta AB


• Heritage Pharmaceuticals Inc

Recent development

No recent development has been reviewed of this Pseudotumor Cerebri Market

Report Overview

This report mainly includes all the details and it tends to initialize the growth along with a better efficiency of the market with particular management. It states that the driving factors have been interrupted due to the sudden covid 19 situations. The entire analysis is based upon the Covid 19 analysis, regional analysis, market overview, segmentation analysis, market dynamics and it mainly includes the challenges, opportunities, restraints, and drivers. Further, the competitive landscape and the other sections are presented. Hence, all of the information that has been collected is from the primary as well as the secondary sources.

Pseudotumor Cerebri Market Segmentation

Pseudotumor Cerebri Diagnosis Outlook

• Fundoscopy


• Lumbar Puncture


• Neuroimaging


• Others

Pseudotumor Cerebri Treatment Outlook

• Surgery


• Medication


• Spinal Fluid Shunt


• Optic Nerve Sheath Fenestration


• Dural Venous Sinus stenting


• Bariatric Surgery

Pseudotumor Cerebri Medication Outlook

• Acetazolamide


• Furosemide


• Steroids


• Topiramate

Pseudotumor Cerebri End-User Outlook

• Hospitals


• Diagnostic Centers


• Clinics


• Drug stores


• Pharmacies


• Others

Pseudotumor Cerebri Regional Outlook

• North America


• Europe


• Asia- Pacific


• Middle-East and Africa


• Other regions of the world